KIT and cancer: In consequence, possible therapeutic pathways for mast cells in cancer include c-kit inhibitors, mast cell stabilizers, activators/inhibitors of the FcεR1 signal pathway, antibodies targeting inhibitory receptors and ligands, and TLR agonists, and mast cell-derived mediators regulators, which target mast cells to ameliorate cancer (Lichterman and Reddy, 2021).